Applications of external cavity diode laser-based technique to noninvasive clinical diagnosis using expired breath ammonia analysis: chronic kidney disease, epilepsy

Ismail Bayrakli
Aysenur Turkmen
Hatice Akman
M. Tugrul Sezer
Suleyman Kutluhan
Applications of external cavity diode laser-based technique to noninvasive clinical diagnosis using expired breath ammonia analysis: chronic kidney disease, epilepsy

Ismail Bayrakli, a,* Aysenur Turkmen, a Hatice Akman, a M. Tuğrul Sezer, b and Suleyman Kutluhan c
a Suleyman Demirel University, Biomedical Engineering, Baltıkampusı Isparta, Turkey
b Suleyman Demirel University, School of Medicine, Department of Nephrology, Doğu kampüsü Isparta, Turkey
c Suleyman Demirel University, School of Medicine, Department of Neurology, Doğu kampüsü, Isparta, Turkey

Abstract. An external cavity laser (ECL)-based off-axis cavity-enhanced absorption spectroscopy was applied to noninvasive clinical diagnosis using expired breath ammonia analysis: (1) the correlation between breath ammonia levels and blood parameters related to chronic kidney disease (CKD) was investigated and (2) the relationship between breath ammonia levels and blood concentrations of valproic acid (VAP) was studied. The concentrations of breath ammonia in 15 healthy volunteers, 10 epilepsy patients (before and after taking VAP), and 27 patients with different stages of CKD were examined. The range of breath ammonia levels was 120 to 530 ppb for healthy subjects and 710 to 10,400 ppb for patients with CKD. There was a statistically significant positive correlation between breath ammonia concentrations and urea, blood urea nitrogen, creatinine, or estimated glomerular filtration rate in 27 patients. It was demonstrated that taking VAP gave rise to increasing breath ammonia levels. A statistically significant difference was found between the levels of exhaled ammonia (NH₃) in healthy subjects and in patients with epilepsy before and after taking VAP. The results suggest that our breath ammonia measurement system has great potential as an easy, noninvasive, real-time, and continuous monitor of the clinical parameters related to epilepsy and CKD. © 2016 Society of Photo-Optical Instrumentation Engineers (SPIE) [DOI: 10.1117/1.JBO.21.8.087004]

Keywords: breath analysis; cavity-enhanced absorption spectroscopy; ammonia; chronic kidney disease; epilepsy.

Paper 160342R received May 28, 2016; accepted for publication Jul. 25, 2016; published online Aug. 16, 2016.

1 Introduction

To date, more than 1000 trace volatile organic compounds (VOCs) have been found in exhaled breath at concentrations ranging from ppmv to pptv.1 The VOCs in exhaled breath can be established as biomarkers for particular diseases and metabolic disorders.1 Ammonia is a proven important VOC in breath. This breath molecule is established as a biomarker for clinical diagnostics, such as hemodialysis monitoring,2 diagnosis of hepatic encephalopathy,3 detection of Helicobacter pylori,4 and halitosis.5 Ammonia is a component of the nitrogen cycle resulting from protein metabolism. Ammonia is present in body fluids in two forms: unionized ammonia (NH₃) and ammonium ion (NH₄⁺). Highly toxic NH₃/NH₄⁺ is converted to less toxic urea in the liver through the urea and citric acid cycles. Urea is transported to the kidneys via the bloodstream and is then removed from the body by the kidneys in urine. For a healthy person, blood ammonia can be filtered out of the body properly and is made harmless by the liver and kidneys. Dysfunction or impairment of these organs gives rise to increasing ammonia levels in the blood, which is diffused into the lungs and can be exhaled in breath. Ammonia at a very high concentration becomes dangerous for the human body. Therefore, ammonia plays a significant role in the human body. Detailed information on ammonia metabolism can be found in Ref. 6.

In most studies, the ammonia concentrations in exhaled breath of healthy subjects alone, or of a small cohort (n < 40) of healthy volunteers and patients, were measured by using different techniques. To our knowledge, up to now, no studies have considered real-time monitoring of breath ammonia in a large cohort of healthy volunteers, patients with chronic kidney disease (CKD), and patients diagnosed with epilepsy and receiving valproic acid (VAP) therapy. A chemoresistive gas sensor has been developed consisting of flame-made nanostructured α-MoO₃, a promising phase for selective detection of breath NH₃. This sensor showed NH₃ selectivity toward acetone, NO, and CO, and accurately detected breath-relevant NH₃ concentrations down to 400 ppb under 90% relative humidity.6 Spacek et al.8 measured breath ammonia in real time by quartz-enhanced photoacoustic spectrometry and blood ammonia in 10 healthy and 10 cirrhotic participants. Ogimoto et al.9 fabricated quartz crystal microbalance (QCM) sensors and showed that the sensors can detect ammonia in human breath at pathological levels (greater than 3 ppm). Spacek et al. used breath analysis of ammonia, ethanol, hydrogen, and acetone to investigate gastrointestinal physiology. In 30 healthy participants, they measured each metabolite serially over 6 h in control and high protein trials.10 Owen and Farooq11 found breath ammonia levels of 100 to 350 ppb in eight healthy individuals and ~1000 to 4500 ppb in three patients diagnosed with CKD. Schmidt et al.12 measured
ammonia concentrations in exhaled breath of 20 healthy subjects on-line with a commercial cavity ring-down spectrometer and found values of 396 to 2133 ppb. Hibbard and Killard used a commercial photoacoustic laser ammonia analyzer to measure real-time levels of ammonia in exhaled human breath in a small normal healthy population (n = 30). They determined an average level of breath ammonia of 265 ppb, ranging from 29 to 688 ppb, and found no correlation between oral breath ammonia and age, sex, body mass index (BMI), or breath carbon dioxide levels. Enderby et al. measured the levels of ammonia in the exhaled breath of 200 healthy school children aged 7 to 18 years by using selected ion flow tube mass spectrometry (SIFT-MS) and found a concentration range of 112 to 2865 ppb. Neri et al. analyzed the breath of 20 patients and 20 healthy volunteers and found a correlation between expired ammonia and blood urea nitrogen (BUN) levels using ion mobility spectrometry (p = 0.002, r = 0.84; p = 0.009, r = 0.76) and cavity ring-down spectroscopy techniques (p = 0.005, r = 0.80; p = 0.008, r = 0.77), respectively, both before and at the end of dialysis. Narasimhan et al. determined breath ammonia levels in seven patients with end-stage renal disease of 1500 to 2000 ppb before hemodialysis and 150 to 200 ppb after hemodialysis. One of these seven patients showed a correlation between breath ammonia and BUN, with $R^2 = 0.95$, and between breath ammonia and creatinine, with $R^2 = 0.83$. The further studies related to breath ammonia measurement can be found in, e.g., review articles. More research in this area is clearly necessary owing to differences in the reported breath ammonia levels.

In the present study, the external cavity laser (ECL)-based off-axis cavity-enhanced absorption spectroscopy (OA-CEAS) was applied to noninvasive clinical diagnosis using expired breath ammonia analysis. For this aim, (1) the correlation between breath ammonia levels and blood parameters related to CKD was investigated and (2) the relationship between breath ammonia levels and blood concentrations of VAP was studied. For this purpose, we measured breath ammonia concentrations and correlated these with blood parameters related to epilepsy and CKD. Thus, venous blood and breathed air in a cohort (n = 52) of patients with CKD (17 men/10 women, aged 45 to 78 years), of healthy volunteers (8 men/7 women, aged 25 to 51 years), and epilepsy patients before and after taking VAP (6 men/4 women, aged 30 to 60 years) were simultaneously sampled. The breath ammonia levels were measured by using ECL-based OA-CEAS. We found breath ammonia levels of 120 to 530 ppb in healthy subjects and 710 to 10,400 ppb in patients with CKD. We observed a statistically significant positive correlation between breath ammonia concentrations and urea, BUN, creatinine, or estimated glomerular filtration rate (eGFR) in all patients. A linear correlation between breath ammonia and urea ($r = 0.69, p = 0.00017), BUN ($r = 0.71, p < 0.0001$), and creatinine ($r = 0.91, p < 0.0001$) was demonstrated. An exponential relationship between breath ammonia and eGFR ($R^2 = 0.84$) was found. It was demonstrated that taking VAP gave rise to increasing breath ammonia levels; a mean of 636 ppb ranging from 250 to 1090 ppb before taking VAP and a mean of 989 ppb ranging from 450 to 1477 ppb after taking VAP. A statistically significant difference was found between the levels of exhaled NH$_3$ in healthy subjects ($p < 0.05$) and in patients with epilepsy before and after taking VAP ($p < 0.05$). But no correlation between the breath ammonia levels and blood VAP concentrations ($r = 0.25, p = 0.29$) was found. The noninvasive technique used in this work can provide rapid routine diagnosis and continuous monitoring of the health status of patients with epilepsy and CKD, e.g., during hemodialysis.

## 2 Human Subjects

The subjects for this study were recruited among workers and patients in the Research and Education Hospital of Suleyman Table 1 Demographic, clinical, and laboratory characteristics of 27 patients suffering from CKD, 10 patients diagnosed with epilepsy, and 15 healthy volunteers participated in the study.

<table>
<thead>
<tr>
<th>Segment</th>
<th>Gender (male/female)</th>
<th>Age (years)</th>
<th>BMI (kg m$^{-2}$)</th>
<th>NH$_3$ (ppb) (Before taking VAP)</th>
<th>NH$_3$ (ppb) (After taking VAP)</th>
<th>Urea (mg/dL)</th>
<th>Creatinine (mg/dL)</th>
<th>eGFR (mL/min/1.73 m$^2$)</th>
<th>VAP (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy control</td>
<td>17/10</td>
<td>Mean: 60, ranging from 45 to 78</td>
<td>Mean: 29, ranging from 20 to 40</td>
<td>Mean: 3221, ranging from 712 to 10,400</td>
<td>Mean: 21, ranging from 6 to 47</td>
<td>Mean: 104, ranging from 30 to 194</td>
<td>Mean: 3.4, ranging from 1.42 to 8.78</td>
<td>Mean: 21, ranging from 6 to 47</td>
<td>Mean: 88.53, ranging from 72.63 to 126.30</td>
</tr>
<tr>
<td>CKD</td>
<td></td>
<td>SD: 11</td>
<td>SD: 5</td>
<td>SD: 23680</td>
<td>SD: 10</td>
<td>SD: 46</td>
<td>SD: 1.7</td>
<td>SD: 10</td>
<td>SD: 10</td>
</tr>
<tr>
<td>Epilepsy</td>
<td></td>
<td>6/4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender (male/female)</td>
<td></td>
<td>Age (years)</td>
<td>BMI (kg m$^{-2}$)</td>
<td>NH$_3$ (ppb) (Before taking VAP)</td>
<td>NH$_3$ (ppb) (After taking VAP)</td>
<td>Urea (mg/dL)</td>
<td>Creatinine (mg/dL)</td>
<td>eGFR (mL/min/1.73 m$^2$)</td>
<td>VAP (min)</td>
</tr>
<tr>
<td>8/7</td>
<td>45, ranging from 30 to 60</td>
<td>30, ranging from 25 to 36</td>
<td>Mean: 636, ranging from 250 to 1090 ppb</td>
<td>Mean: 989, ranging from 450 to 1477</td>
<td>Mean: 88.53, ranging from 72.63 to 126.30</td>
<td>Mean: 21, ranging from 6 to 47</td>
<td>Mean: 21, ranging from 6 to 47</td>
<td>Mean: 88.53, ranging from 72.63 to 126.30</td>
<td>Mean: 88.53, ranging from 72.63 to 126.30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Segment</th>
<th>Gender (male/female)</th>
<th>Age (years)</th>
<th>BMI (kg m$^{-2}$)</th>
<th>NH$_3$ (ppb)</th>
<th>VAP (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy control</td>
<td>17/10</td>
<td>Mean: 60, ranging from 45 to 78</td>
<td>Mean: 29, ranging from 20 to 40</td>
<td>Mean: 3221, ranging from 712 to 10,400</td>
<td>Mean: 21, ranging from 6 to 47</td>
</tr>
<tr>
<td>CKD</td>
<td></td>
<td>SD: 11</td>
<td>SD: 5</td>
<td>SD: 23680</td>
<td>SD: 10</td>
</tr>
<tr>
<td>Epilepsy</td>
<td></td>
<td>6/4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender (male/female)</td>
<td></td>
<td>Age (years)</td>
<td>BMI (kg m$^{-2}$)</td>
<td>NH$_3$ (ppb)</td>
<td>VAP (min)</td>
</tr>
<tr>
<td>8/7</td>
<td>45, ranging from 30 to 60</td>
<td>30, ranging from 25 to 36</td>
<td>Mean: 636, ranging from 250 to 1090 ppb</td>
<td>Mean: 989, ranging from 450 to 1477</td>
<td>Mean: 88.53, ranging from 72.63 to 126.30</td>
</tr>
</tbody>
</table>
Demirel University. Fifteen healthy volunteers (7 women/8 men, aged 25 to 51 years), 10 epilepsy patients diagnosed with epilepsy and receiving VAP therapy (6 men/4 women, aged 30 to 60 years), and 27 patients with CKD (10 women/17 men, aged 45 to 78 years) participated in the study. Exclusion criteria were active infection, cancer, H. pylori infection, liver failure, and pregnancy. Smokers and subjects who consumed alcohol were not included in the study. For biochemical analysis, venous blood samples were collected at the same time as breath ammonia measurements. The demographic, clinical, and laboratory characteristics of patients and healthy subjects are compiled in Table 1.

The subjects were required to fast overnight. All samples were taken in the hospital between 08:00 and 11:00 AM. Information was collected regarding age, height and weight, medication, smoking, and alcohol use. The research was approved by the ethics committee of the hospital; all volunteers gave their written informed consent to participate in the study.

3 Methods

Details of the experimental setup (ECL-based OA-CEAS) used in this study are presented in our earlier work (Fig. 1). Briefly, a broadly coarse wavelength tuning range of 170 nm (720 cm⁻¹) for the spectral range between 1451 and 1621 nm is achieved by rotating the diffraction grating forming ECL configuration in single-mode operation. A mode-hop-free tuning range of 1.85 cm⁻¹ is obtained. The linewidths below 140 kHz are recorded. Using the absorption line of ammonia at 6528.76 cm⁻¹, detection limit of ~40 ppb is demonstrated for 512 averages.

The laser beam is coupled into the CEAS cavity in the OA alignment via a 50-cm lens and a mirror. The cavity consists of two high reflective mirrors positioned 50 cm apart with a reflectivity of >99.96% over the spectral range between 700 and 1650 nm with a 2.54-cm diameter and a radius of curvature of 1 m (LayerTeC GmbH). The radiation exiting the cavity is the mirror reflectivity, and d (50 cm) is the distance between the cavity mirrors.

The NH₃ absorption line at 6528.76 cm⁻¹ is an isolated line and suitable for breath analysis. The following procedures for breath collection and analysis are performed to remove residual ammonia in the cell and to prepare the system for the next sample. The alveolar air sample is collected using a mouthpiece, flutter valve, T-connector, collection bag, and discard bag (Quintron). The separation of the dead-space air from alveolar air is performed by using the disposable polyethylene discard bag. The expired breath air, containing “dead-space” air, is first directed into the discard bag, and then the alveolar air is diverted to the collection bag. To deliver the alveolar air sample collected in the collection bag into the quartz-coated sample cell (CRD Optics), a two-way nonrebreathing valve (Hans Rudolph, Inc.) and a mass flow controller calibrated for exhaled breath (Alicat, MCV-2SLPM-D/5M) are used. Before taking measurements, the cell is evacuated using a vacuum pump (Agilent, IDP3) to the minimum achievable value (7 x 10⁻² mbar), and is then flushed with indoor air for 30 min, because the H₂O molecules in indoor air aid to remove NH₃ from the cell. After filling the cell with pure N₂ to a total pressure of 1000 mbar, it is again evacuated. The cell is heated to 35 to 40°C for desorption of ammonia adhered on the mirror surfaces and walls of the cell. The measurement is carried out at a reduced pressure of 50 mbar. The flow rate of the mass flow controller is 1500 sccm.

An example for the transmission signal through the CEAS cell filled with alveolar air is depicted in Fig. 2(a). From this Figure, the isolated absorption line of NH₃ at 6528.76 cm⁻¹ and the absorption line of NH₃ and CO₂ at 6528.89 cm⁻¹ can be seen. The line strengths are 2.5 x 10⁻²¹ cm⁻¹/molecule cm⁻² for the NH₃ absorption line at 6528.76 cm⁻¹, 1.24 x 10⁻²⁰ cm⁻¹/molecule cm⁻² for the NH₃ absorption line at 6528.89 cm⁻¹, and 5.2 x 10⁻²⁵ cm⁻¹/molecule cm⁻² for the CO₂ absorption line at 6528.895 cm⁻¹, respectively. In Fig. 2(b), the data in units of percent transmission and FPI peaks are plotted. In Fig. 2(c), the absorption coefficient of NH₃ at 6528.76 cm⁻¹, which is calculated according to Eq. (1), and Voigt fit through the experimental data points are depicted.

$$\alpha = \left( \frac{I_0}{I} \right) \left( 1 - \frac{R}{d} \right),$$  \hspace{1cm} (1)

where $I_0$ is the baseline signal, $I$ is the recorded CEAS signal, $R$ is the mirror reflectivity, and $d$ (50 cm) is the distance between the cavity mirrors.

To determine the line strength $S$, the integrated CEAS signal is plotted as a function of the pressure in our previous work. The slope of the linear fit through the data points gives a value for $S$ of 2.5 x 10⁻²¹ cm⁻¹/molecule cm⁻², which is in agreement with the result reported by Webber et al. In our earlier study, the absorption coefficient of NH₃ at 6528.76 cm⁻¹ was calculated using the Voigt fit through the experimental data points.
The ammonia concentration is calculated from the line strength, the area under the absorption line, and the total molecule concentration.

The measurements for breath ammonia concentrations were repeated to determine how much of the statistical variation is due to measurement error [Fig. 3(a)]. The mean is 3140 ppb ranging from 3105 to 3178 ppb, the standard deviation (SD) is 26 ppb, and the standard error (SE) is 12 ppb. In order to determine the linear dynamic range, breath ammonia concentration is plotted versus absorption coefficient and area under absorption coefficient over the entire measurement range of the CKD. As shown in Fig. 3(b), the plot is linear for absorption coefficient ($R = 0.994, p < 0.0001$) and area ($R = 0.995, p < 0.0001$).

4 Results

4.1 Chronic Kidney Disease

To measure the eGFR, creatinine, and BUN levels, venous blood samples were taken from volunteers during routine examination. We measured the breath ammonia levels by using ECL-based OA-CEAS technique, and found a range of 120 to 530 ppb for healthy subjects with apparently normal liver and kidney function, and 710 to 10,400 ppb in patients. We observed a good correlation between breath ammonia and serum urea, BUN, creatinine, or eGFR in 27 patients. In Fig. 4, the squares correspond
to the experimental data, and the solid lines show fits to the data. A linear correlation between breath ammonia and urea ($r = 0.69, p = 0.00017$), BUN ($r = 0.71, p < 0.0001$), or creatinine ($r = 0.91, p < 0.0001$) was observed. An exponential relationship between breath ammonia and eGFR ($R^2 = 0.84$) was found.

### 4.2 Epilepsy

We used a box-plot analysis to compare the concentrations of ammonia in exhaled breath of epilepsy patients before and after taking VAP and of healthy subjects (Fig. 5). The box-plot analysis is a statistical analysis technique and can be utilized to demonstrate the distribution of a dataset through their quartiles. From the box plot, a mean of 323 ppb ranging from 120 to 530 ppb was obtained from the breath ammonia of healthy volunteers, while the breath ammonia levels of epilepsy patients were ranged from 250 to 1090 ppb with a mean of 636 ppb before taking VAP and from 450 to 1477 ppb with a mean of 989 ppb after taking VAP (Table 2). Therefore, an increased concentration of exhaled ammonia in patients after taking VAP was observed in comparison to those before taking VAP. The concentrations of breath ammonia in healthy people were found to be lower than the levels in epilepsy patients. A statistically significant difference was found between the levels of exhaled NH$_3$ in healthy subjects ($p < 0.05$) and in patients with epilepsy before and after taking VAP ($p < 0.05$). We observed no correlation between the breath ammonia levels and blood VAP concentrations ($r = 0.25, p = 0.29$).

### 5 Discussion

#### 5.1 Technique Used in the Present Work: OA-CEAS

Currently, invasive techniques are used to detect the biomarkers that cause significant discomfort to the patient. There is therefore a desire to develop noninvasive techniques of detection. Furthermore, a technique that does not require special training is needed for point-of-care use. The noninvasive breath analysis technique, especially the laser-based method, is a good candidate for this purpose.

Despite of the long history of breath test, there are still several issues that should be addressed for routine clinical use of breath analysis in hospitals. Among others, it is very important to develop the easy-to-use, high sensitive, high selective, portable, compact, real-time, and low construction and maintenance cost devices operating at room temperature. Such devices are currently being developed.

Detection methods, such as gas chromatography mass spectrometry, SIFT-MS, and proton transfer reaction mass spectrometry are not ideal for practical application in hospitals because they are expensive, bulky, complex, time consuming, and require complicated procedures for sample collection and preconcentration. The laser-based optical techniques, such as OA-CEAS, photoacoustic spectroscopy (PAS), cavity ringdown spectroscopy (CRDS), and multipass cell absorption method, are more compact and can provide real-time analysis without the need for preconcentration.

There are commercially available PAS and CRD sensors on the market. PAS sensors are highly sensitive to mechanical and acoustic vibrations, whereas their small size is the main advantage of such sensors. The CRDS method requires high-speed electronics. The OA-CEAS technique used in the present work has several advantages over the other laser-based techniques; it is almost insensitive to vibrations and to fluctuations in pressure and temperature, there is no need for active locking and high-speed electronics, and alignment is simpler. These advantages make the OA-CEAS instrument more suitable for measurements outside the laboratory environment. In our present system, a

### Table 2 Minimum, maximum, quartiles, and mean values of concentrations of exhaled ammonia.

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Before taking VAP</th>
<th>25% (ppb)</th>
<th>50% (ppb)</th>
<th>75% (ppb)</th>
<th>Max (ppb)</th>
<th>Mean (ppb)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ammonia</td>
<td>250</td>
<td>490</td>
<td>555</td>
<td>848</td>
<td>1090</td>
<td>636</td>
</tr>
<tr>
<td></td>
<td>After taking VAP</td>
<td>450</td>
<td>787</td>
<td>933</td>
<td>1200</td>
<td>1477</td>
</tr>
<tr>
<td>Control</td>
<td>120</td>
<td>171</td>
<td>340</td>
<td>467</td>
<td>530</td>
<td>323</td>
</tr>
</tbody>
</table>

Fig. 5 (a) Box plot comparison of exhaled breath ammonia levels from healthy volunteers and epilepsy patients before and after taking VAP and (b) breath ammonia versus VAP correlation in 10 epilepsy patients.
cheaper laser source and electronics are used in comparison to other commercially available ammonia sensors. Furthermore, our system is able to analyze the breath VOCs in a broad spectral range between 700 and 1620 nm. These could be further highlighted as advantages.

The chance of the potential commercial realization of the present technology in a hospital setting can be further increased by the miniaturization of our system. Therefore, miniature optical components, such as in ECLs from Daylight Solutions, should be used. An all-in-one laser diode controller (e.g., MOGbox DLC202 from Moglabs) can be utilized for a more compact setup. Such a controller includes ultralow-noise current driver, temperature controller, ramp generator, piezodrivers, modulator, demodulator (lock-in amp), servo feedback system, and photodetector. A CEAS absorption cell with smaller physical length can be designed by using the mirrors with larger diameter to compensate the detection limit, which is achieved with larger cell length. To further decrease the size of the system, PAS cell can be alternatively used.

5.2 Chronic Kidney Disease

The eGFR is used to evaluate how well the kidneys are working and to determine the stage of kidney disease. This test estimates how much blood passes through the glomeruli (the tiny filters in the kidneys) per minute and, therefore, provides information about the volume of blood that is filtered by the kidneys over a given time period. If these filters do not work properly, the kidneys have a reduced or impaired function. The eGFR test is based on the measurements of the creatinine in the blood. Creatinine should be removed from the blood by the kidneys. If kidney function is abnormal, the creatinine level in the blood increases. The eGFR is calculated considering the age, sex, blood creatinine level, and ethnicity. The eGFR can be used to diagnose kidney disease in its early stages more reliably than the creatinine test. The eGFR level suggests the severity of kidney disease: if more than 90 mL/min, the kidneys are working properly; if it is between 90 and 15 mL/min, the kidneys are not working as well as they should (there is kidney disease); and if less than 15 mL/min, it indicates kidney failure. However, the eGFR is not useful for everyone. This is not a good test for people who are younger than 18 years, pregnant, overweight, or very muscular.

The liver produces ammonia and forms urea by combining nitrogen with other elements, such as carbon, hydrogen, and oxygen. The urea is transported from the liver to the kidneys through the bloodstream. The urea can be filtered properly by healthy kidneys. Urea and other waste products can be removed from the body through urine. The BUN test measures the amount of urea nitrogen in the blood and provides information about how well the kidneys and liver are working.

Narasimhan et al. found a correlation between breath ammonia and BUN ($R^2 = 0.95$), and between breath ammonia and creatinine ($R^2 = 0.83$) for one of seven patients. 

The ammonia concentrations in mouth-exhaled breath, nose-exhaled breath, and in the oral cavity have been measured and found that the mount-exhaled NH$_3$ concentration is lower than the NH$_3$ concentration in the oral cavity and higher than the nose-exhaled NH$_3$ concentration, indicating that mouth-exhaled NH$_3$ is also produced in the oral cavity, in addition to the alveoli. In a recently published study, it is claimed that the origin of NH$_3$ in the oral cavity is the oral fluid urea. However, it is known that salivary urea correlates very well to serum urea.

Zuniga et al. reported that the salivary urea test has the potential to be used as a method to discriminate patients with CKD. Therefore, the salivary urea cannot be seen independently from the serum urea.

Imran et al. observed no relationship between eGFR and blood ammonia ($p = 0.207$). The difference in breath ammonia concentrations and blood ammonia levels observed in CKD patients could be explained by differences in the mucus membranes in the oral cavity and in pulmonary alveoli. Therefore, a portable, accurate, easy-to-use, real-time breath ammonia measurement system can be very useful to simplify noninvasive, online, and continuous assays of eGFR, creatinine levels, and other clinical parameters related to CKD. Our system can be utilized in the future for this purpose.

5.3 Epilepsy

A blood–brain barrier protects the brain from entering toxins. The permeability of the blood–brain barrier can be modified by the components, such as glutamine, which is produced from the irregular synthesis of the urea cycle. Increased glutamine levels can then change the osmotic tendencies around brain tissue giving rise to swelling of the brain. Ammonia becomes neurotoxic at higher concentrations. Excessive cerebral ammonia can lead to astrocytic glutamine accumulation and cerebral oedema. Ammonia entering the brain is able to affect the gene expression and signal transmission of neurons.

The breath ammonia is established as a biomarker for clinical diagnostics of neurological diseases, such as hepatic encephalopathy, which is a consequence of advanced liver disease. Liver dysfunction is usually accompanied by hyperammonemia (increasing the blood ammonium levels). Hyperammonemia has been also reported to be associated with patients taking VAP. An increased concentration of ammonia in blood can probably result in increasing of breath ammonia levels of epilepsy patients. VAP, a branched short-chain fatty acid, is an antiepileptic drug commonly used in the treatment of epilepsy, migraine, and psychiatric disorders.

For the first time, to our knowledge, the correlation between breath ammonia levels and blood VAP concentrations was investigated in the present study. In the future, our breath ammonia measuring system has a potential to use in the treatment of epilepsy. More comprehensive studies are necessary in this area.

6 Conclusions

We applied the ECL-based OA-CEAS to noninvasive clinical diagnosis using expired breath ammonia analysis: (1) the correlation between breath ammonia levels and blood parameters related to CKD was investigated and (2) the relationship between breath ammonia levels and blood concentrations of VAP was studied. The concentrations of breath ammonia in 15 healthy volunteers, 10 epilepsy patients (before and after taking VAP), and 27 patients with different stages of CKD were measured. We found a range of breath ammonia levels of 120 to
530 ppb in healthy subjects and 710 to 10,400 ppb in patients with CKD. A statistically significant linear correlation between breath ammonia and urea ($r = 0.69$, $p = 0.00017$), BUN ($r = 0.71$, $p < 0.0001$), or creatinine ($r = 0.91$, $p < 0.0001$) in 27 patients with CKD was demonstrated. An exponential relationship between breath ammonia and eGFR ($R^2 = 0.84$) was found. The breath ammonia levels were determined to be between 250 and 1090 ppb before taking VAP, and between 450 and 1477 ppb after taking VAP. A statistically significant difference was found between the levels of exhaled NH3 in healthy subjects ($p < 0.05$) and in patients with epilepsy before and after taking VAP ($p < 0.05$). However, no significant correlation between the breath ammonia levels and blood VAP concentrations ($r = 0.25$, $p = 0.29$) was shown. The experimental results show the possibility of using our real-time breath ammonia measurement system for rapid routine diagnosis and continuous monitoring of the health status of patients with epilepsy and CKD.

Acknowledgments

We gratefully acknowledge financial support by the Scientific and Technological Research Council of Turkey (TUBITAK, 112E559) and Suleyman Demirel University (SDU BAP, 3917-D2-14).

References


Ismail Bayrakli is an assistant professor at Suleyman Demirel University. He received his MSc degree in 2005 and PhD in physics.
in 2008 from the Technical University of Berlin and Humboldt University, Berlin, Germany. His research interests include tunable single- and double-mode diode lasers, ultrasensitive and ultraresolution laser-based biomedical sensors, and breath analysis.

Aysenur Turkmen received her BSc degree in electronic and telecommunication engineering from Suleyman Demirel University in 2013. Since 2013, she has been an MSc student at Suleyman Demirel University.

Hatice Akman is a research assistant at Suleyman Demirel University. She received her MSc degree in electronic and telecommunication engineering from Suleyman Demirel University in 2011. Since 2012, she has been a PhD student at Suleyman Demirel University.

M. Tugrul Sezer is a professor at Suleyman Demirel University. He received his MSc degree in 1986 and a PhD in medicine in 1993 from Akdeniz University, Turkey.

Suleyman Kutluhan is a professor at Suleyman Demirel University. He received his MSc degree in 1981 and a PhD in medicine in 1986 from Ege University, Turkey.